NICE error means breathing room for Lilly's Alimta
This article was originally published in Scrip
Lilly has won a little extra breathing room to convince NICE, the health technology appraisal institute for England and Wales, to recommend its lung cancer drug Alimta (pemetrexed) after the institute made a procedural error in the appraisal process. NICE has had to retract previous negative final draft guidance and publish new draft recommendations rather than proceeding to final guidance
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.